XenoPort Announces Presentation of Preclinical Data for Acamprosate Prodrug at Fragile X Syndrome Conference

Published July 23, 2010

XenoPort Announces Presentation of Preclinical Data for Acamprosate Prodrug at Fragile X Syndrome Conference
SANTA CLARA, Calif.—-XenoPort, Inc. announced today that it has discovered a novel prodrug that has the potential to improve significantly the blood concentration of acamprosate compared with the currently approved formulation of acamprosate.
Read more on Business Wire via Yahoo! Finance